$87.38 -$1.76 (-2.0%)

04:30 PM EDT on 04/18/19

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

CAPS Rating: 4 out of 5

Current Price $87.38 Mkt Cap $2.7B
Open $89.40 P/E Ratio 0.00
Prev. Close $89.14 Div. (Yield) $0.00 (0.0%)
Daily Range $86.51 - $90.23 Volume 547,168
52-Wk Range $86.51 - $131.87 Avg. Daily Vol.

Caps

How do you think NASDAQ:ICPT will perform against the market?

Add Stock to CAPS Watchlist

All Players

94 Outperform
33 Underperform
 

All-Star Players

32 Outperform
6 Underperform
 

Wall Street

7 Outperform
2 Underperform
 

Top NASDAQ:ICPT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Emjae06 (< 20)
Submitted January 11, 2014

Maybe it would continue to go up.

NewbiesRock (< 20)
Submitted February 18, 2014

I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good… More

NASDAQ:ICPT VS S&P 500 (SPY)

Fools bullish on NASDAQ:ICPT are also bullish on:

Fools bearish on NASDAQ:ICPT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ICPT.

Recs

0
Member Avatar Bigsef77 (67.51) Submitted: 2/19/2019 10:07:10 AM : Outperform Start Price: $62.44 NASDAQ:ICPT Score: +32.95

Intercept up 23% premarket on positive OCA data
Feb. 19, 2019 7:43 AM ET|About: Intercept Pharmaceuticals (ICPT)|By: Douglas W. House, SA News Editor

Intercept Pharmaceuticals (NASDAQ:ICPT) is up 23% premarket on light volume following its announcement of positive results from a Phase 3 clinical trial, REGENERATE, evaluating obeticholic acid (OCA) in patients with liver fibrosis (scarring) due to nonalcoholic steatohepatitis (NASH).

The study met one co-primary endpoint, a statistically significant proportion of patients achieving at least one stage improvement in fibrosis with no worsening of NASH at month 18 (p=0.0002), but failed to meet the other, the proportion of patients achieving NASH resolution with no worsening of liver fibrosis. The FDA agreed that only one endpoint needed to be met in order to be judged successful.

The data will be presented at the European Association for the Study of the Liver (EASL): International Liver Congress in Vienna April 10 - 14.

The company plans to file a U.S. marketing application in H2.

See all stocks on the move »

Recs

0
Member Avatar XMFRendezvous (94.23) Submitted: 4/21/2018 6:10:02 PM : Outperform Start Price: $69.05 NASDAQ:ICPT Score: +18.04

"NASH is a megablockbuster indication with no currently approved treatments. OCA is well positioned to address this huge market opportunity."

http://www.morningstar.com/stocks/xnas/icpt/quote.html

5 Star Morningstar Stock.

Recs

0
Member Avatar TurksFan (44.50) Submitted: 4/7/2018 8:43:26 AM : Outperform Start Price: $72.56 NASDAQ:ICPT Score: +9.47

Starting my research into biotechs

Leaderboard

Find the members with the highest scoring picks in ICPT.

Score Leader

alkusari

alkusari (< 20) Score: +443.87

The Score Leader is the player with the highest score across all their picks in ICPT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
vzwatmrk < 20 1/10/2014 Underperform 5Y $455.50 -80.82% +58.02% +138.84 0 Comment
Halffrenzy 25.72 1/10/2014 Underperform 5Y $438.98 -80.09% +58.34% +138.43 0 Comment
jjc007007 63.22 2/5/2014 Underperform 5Y $296.00 -70.48% +65.25% +135.73 0 Comment
sinvestor 65.89 1/14/2014 Underperform 3M $361.00 -75.80% +59.10% +134.89 1 Comment
kevrose31 77.80 1/10/2014 Underperform 1Y $373.00 -76.57% +57.65% +134.23 0 Comment
NewbiesRock < 20 2/18/2014 Underperform 5Y $353.89 -75.31% +57.45% +132.75 4 Comments
Figgie27 < 20 1/13/2014 Underperform 3M $339.87 -74.29% +57.86% +132.15 0 Comment
alexeysm 31.04 1/13/2014 Underperform 1Y $339.87 -74.29% +57.86% +132.15 0 Comment
kayakmastr 91.99 1/13/2014 Underperform 1Y $339.87 -74.29% +57.86% +132.15 0 Comment
gillet01 74.92 4/7/2014 Underperform 5Y $298.86 -70.76% +56.86% +127.62 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRBCCapMkts 85.46 3/1/2019 Outperform NS $103.16 -15.30% +3.41% -18.71 0 Comment
TrackJPMorgan 84.57 1/31/2019 Outperform NS $117.20 -25.44% +8.41% -33.85 0 Comment
TrackUltraLong < 20 11/3/2017 Outperform 5Y $62.00 +40.94% +12.50% +28.43 1 Comment
TrackJimCramer 85.97 3/2/2016 Underperform 3W $119.37 -26.80% +45.73% +72.53 0 Comment
TrackRWBaird 89.13 12/4/2014 Outperform NS $139.99 -37.58% +39.73% -77.31 0 Comment
TrackFBRCapitalM 85.86 8/15/2014 Underperform NS $292.33 -70.11% +47.61% +117.71 0 Comment
TrackDeutscheSec 83.19 7/15/2014 Outperform NS $226.00 -61.34% +46.67% -108.01 0 Comment
TrackJimCramer 85.97 4/3/2014 Outperform 3W $321.81 -62.91% +5.50% -68.40 3/2/2016 @ $119.37 0 Comment
TrackCitigroup 91.25 3/14/2014 Outperform NS $467.00 -81.29% +56.93% -138.22 0 Comment
TrackJimCramer 85.97 1/9/2014 Underperform 3W $275.87 +16.65% +2.72% -13.94 4/3/2014 @ $321.81 0 Comment
TrackJanney 83.53 2/21/2013 Outperform NS $37.24 +134.64% +92.10% +42.54 0 Comment

Advertisement